Dante J. Pieramici, MD, and Lloyd Clark, MD, define age-related macular degeneration (AMD) and highlight the role of antioxidant vitamins in preventing vision loss.
Management of Wet Age-Related Macular Degeneration
Roger A. Goldberg, MD, MBA, and Lloyd Clark, MD, provide insight on initial symptoms patients typically present with in wet AMD.
Lloyd Clark, MD, leads the discussion on the differential diagnosis of wet AMD and the optimal approach to an accurate diagnosis.
A panel of eye care specialists review tests used in clinical practice to screen patients for wet AMD and comment on the clinical benefit of early intervention in patients.
Lloyd Clark, MD, leads the discussion on the goals of therapy for patients with wet AMD and the role of anti-VEGF agents for treatment.
Roger A. Goldberg, MD, MBA, discusses the evolution of therapy from pre– to post–anti-VEGF agents for patients with wet AMD.
A panel of eye care specialists review the 4 currently available anti-VEGF agents available for the treatment of wet AMD.
Lloyd Clark, MD, and Roger A. Goldberg, MD, MBA, share the process for giving injections in the eye for patients who have wet AMD.
Dante J. Pieramici, MD, leads the discussion on factors to consider when selecting the optimal therapy for patients with wet AMD.
Dante J. Pieramici, MD, leads the discussion on the use of VEGF inhibitors for retinal diseases other than wet AMD.
Dante J. Pieramici, MD, and Lloyd Clark, MD, provide insight on approaching the treatment of wet AMD with intravitreal injections and discuss creating a tailored treatment regimen for patients.
A panel of eye care specialists review challenges faced with the management of wet AMD when patients are put on an extended treatment regimen.
Dante J. Pieramici, MD, leads the discussion on potential safety issues of anti-VEGF agents and addressing these concerns with patients who have wet AMD.
Dante J. Pieramici, MD; Roger A. Goldberg, MD, MBA; and Lloyd Clark, MD, review novel compounds in development for the treatment of wet AMD.
A panel of eye care specialists share clinical advice and future directions for the treatment of wet AMD.
Advertisement
Advertisement
Trending on HCPLive
1
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
2
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
3
New Nonsteroidal Options Are Reshaping Pediatric Atopic Dermatitis Care
4
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
5